Journal article

SYNTHESIS OF NEW SPIRO[AZETIDINE-2,3ʹ-INDOLINE]-2ʹ,4-DIONES AS POSSIBLE ANTICANCER AGENTS: IN VITRO AND IN SILICO STUDIES


Research Areas

Currently no objects available


Publication Details

Author list: Abubakar, M. N., García- Sánchez, R., Requena, R., Reyes-Espinosa, F., Juarez- Saldivar, A., Bocanegra-Garcia, V., Rivera, G., Singh, G. S.

Publication year: 2019

Journal acronym: EJBPS

Volume number: 6

Issue number: 2

Start page: 89

End page: 100

Number of pages: 12

ISSN: 2349-8870

URL: https://www.researchgate.net/publication/336042220_SYNTHESIS_OF_NEW_SPIROAZETIDINE-23-INDOLINE-24-DIONES_AS_POSSIBLE_ANTICANCER_AGENTS_IN_VITRO_AND_IN_SILICO_STUDIES

Languages: English



The paper describes the synthesis, and in vitro and in silico biological evaluation of twelve new spiro[azetidine-2,3ʹ-indoline]-2ʹ,4-diones as possible anti-cancer agents. A series of six compounds have been synthesized by a 1:2 molar reaction of 3-(N-substituted)imino-5-chloroisatin with 2-diazo-1,2-diphenylethanone. Treatment of the products with ethanolic sodium hydroxide leads to the formation of a new series of six spiro[azetidine-2,3ʹ- indoline]-2ʹ,4-diones bearing free-NH on 2-oxindole ring. The compounds have been characterized based on analytical and spectral data. The biological evaluation in vitro on breast cancer cells (MDA-MB-231 and MCF-7) was performed. Additionally, an in silico analysis on active site of MDM2 protein was done to understand potential mechanism of action as anti-cancer agents. The compounds 6a, 6c and 6f exhibited cytotoxic activity (IC50 from 2.24 to 22.8 μM) against MDA-MB-231 and MCF-7 cells. Regarding breast cancer cell versus breast normal cells (MCF10A) or normal cells (3T3-L1) 6a, 6c and 6f showed selectivity for growth inhibition of cancerous cells. Molecular docking analysis revealed an equal binding pattern between compound 6a and compound spiro-oxindole 6SS (a potent MDM2 inhibitor) on active site of MDM2 protein.


Projects

Currently no objects available


Keywords

Currently no objects available


Documents

Currently no objects available


Last updated on 2022-29-11 at 11:35